| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IPP |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-584aa |
| 活性数据 | MANEDCPKAADSPFSSDKHAQLILAQINKMRNGQHFCDVQLQVGQESFKAHRLVLAASSPYFAALFTGGMKESSKDVVPILGIEAGIFQILLDFIYTGIVNIGVNNVQELIIAADMLQLTEVVHLCCEFLKGQIDPLNCIGIFQFSEQIACHDLLEFSENYIHVHFLEVHSGEEFLALTKDQLIKILRSEELSIEDEYQVFLAAMQWILKDLGKRRKHVVEVLDPIRFPLLPPQRLLKYIEGVSDFNLRVALQTLLKEYCEVCKSPKENKFCSFLQTSKVRPRKKARKYLYAVGGYTRLQGGRWSDSRALSCVERFDTFSQYWTTVSSLHQARSGLGVTVLGGMVYAIGGEKDSMIFDCTECYDPVTKQWTTVASMNHPRCGLGVCVCYGAIYALGGWVGAEIGNTIERFDPDENKWEVVGNMAVSRYYFGCCEMQGLIYVIGGISNEGIELRSFEVYDPLSKRWSPLPPMGTRRAYLGVAALNDCIYSVGGWNETQDALHTVEKYSFEEEKWVEVASMKVPRAGMCVVAVNGLLYVSGGRSSSHDFLAPGTLDSVEVYNPHSDTWTEIGNMITSRCEGGVAVL |
| 分子量 | 91.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于重组蛋白研究常见方向的假设性参考文献示例(请注意，这些为示例性质，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "High-yield production of recombinant human IPP protein in Escherichia coli for biochemical studies"
**作者**: Müller, A., et al.
**摘要**: 该研究描述了一种高效表达重组人IPP蛋白的大肠杆菌系统，通过密码子优化和诱导条件优化，实现了可溶性蛋白的高产，并证实其酶活性，为后续生化研究提供基础。
2. **文献名称**: "Crystal structure of human IPP synthase and its role in isoprenoid biosynthesis"
**作者**: Garcia, L., et al.
**摘要**: 报道了人源IPP合成酶的晶体结构，揭示了其催化异戊烯焦磷酸合成的分子机制，并通过重组蛋白验证了突变体对代谢通路的影响。
3. **文献名称**: "Immunomodulatory effects of recombinant human IPP protein on γδ T cell activation"
**作者**: Tanaka, R., et al.
**摘要**: 研究重组人IPP蛋白作为γδ T细胞激活配体的作用，发现其可通过TCR信号通路增强抗肿瘤免疫反应，提示其免疫治疗潜力。
4. **文献名称**: "Recombinant IPP protein as a novel biomarker for early cancer detection"
**作者**: Chen, H., et al.
**摘要**: 探讨重组人IPP蛋白在血清中的表达水平与多种癌症的关联性，开发基于该蛋白的ELISA检测方法，有望用于早期诊断。
---
**注意**：以上文献为模拟示例，若需真实文献，建议通过PubMed或Google Scholar使用关键词“recombinant human IPP protein”“isopentenyl pyrophosphate synthase”“IPP immunomodulation”等进一步检索。如IPP指代特定蛋白(如细菌来源的免疫蛋白)，请提供全称以便精准查找。
Recombinant human IPP (Intestinal Permeability-Regulating Protein) is a genetically engineered protein derived from the human gene encoding IPP, which plays a critical role in maintaining intestinal barrier integrity. IPP is primarily expressed in intestinal epithelial cells, where it modulates tight junction dynamics to regulate paracellular permeability. Dysregulation of IPP has been linked to gastrointestinal disorders such as inflammatory bowel disease (IBD), leaky gut syndrome, and metabolic endotoxemia, highlighting its importance in gut homeostasis and immune regulation.
The recombinant version is produced using expression systems like *E. coli* or mammalian cell cultures, enabling large-scale synthesis for research and therapeutic applications. Its production involves cloning the IPP gene into expression vectors, followed by purification via chromatographic techniques. Recombinant IPP retains the biological activity of the native protein, facilitating studies on its molecular mechanisms, including interactions with zonula occludens (ZO) proteins and signaling pathways like NF-κB.
Current research focuses on leveraging recombinant IPP to develop therapies for gut-related diseases, drug delivery systems, and diagnostic tools. Preclinical studies suggest its potential in restoring mucosal barriers and reducing systemic inflammation. However, challenges such as protein stability, targeted delivery, and immunogenicity require further optimization. Ongoing advancements in protein engineering and gut microbiome research continue to expand its biomedical relevance.
×
